KYMR (Kymera Therapeutics) Institutional Ownership: 116.96% (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYMR Kymera Therapeutics Inc KYMR
46 GF Score
Price $100.16
GF Value $24.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kymera Therapeutics Institutional Ownership?

Kymera Therapeutics KYMR -3.00% 46 Institutional Ownership is 116.96% as of Aug. 03, 2026. GuruFocus rates KYMR with a GF Score™ of 46/100 and a GF Value™ of $24.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kymera Therapeutics's institutional ownership is 116.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kymera Therapeutics's Insider Ownership is 1.60%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kymera Therapeutics's Float Percentage Of Total Shares Outstanding is 77.48%.

Kymera Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Kymera Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kymera Therapeutics Institutional Ownership Chart

Kymera Therapeutics Historical Data

The historical data trend for Kymera Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 56.66 57.58 58.19 58.18 58.63 61.73 65.24 65.79 66.41 69.18
KYMR
46GF Score
Kymera Therapeutics Inc KYMR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kymera Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 116.96% mean?
Kymera Therapeutics (KYMR) has a Institutional Ownership of 116.96% as of Aug. 03, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kymera Therapeutics and its competitors.
Is Kymera Therapeutics' Institutional Ownership too high?
Kymera Therapeutics' current Institutional Ownership is 116.96%. Overall, Kymera Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kymera Therapeutics' Institutional Ownership compare to PRAX and SYRE?
Kymera Therapeutics' Institutional Ownership of 116.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Kymera Therapeutics and its competitors. Kymera Therapeutics's current Institutional Ownership is 116.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kymera Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Kymera Therapeutics (KYMR) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.38, compared to a current price of $100.16 — trading 310.8% above its estimated fair value. The current Institutional Ownership is 116.96%. Kymera Therapeutics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Kymera Therapeutics (KYMR), the current Institutional Ownership is 116.96% as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kymera Therapeutics (KYMR) Overvalued in 2026?

Based on GuruFocus' analysis, Kymera Therapeutics stock appears to be overvalued. The current stock price of $100.16 is trading 310.8% above its estimated GF Value™ of $24.38. GuruFocus considers Kymera Therapeutics to be Significantly Overvalued.

Key valuation signals for KYMR:

  • Institutional Ownership: 116.96%
  • GF Value™: $24.38 vs. price of $100.16 (310.8% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the KYMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kymera Therapeutics Business Description

Address 500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
46GF Score

Get the complete analysis for KYMR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.16
Price
$24.38
GF Value